• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    ProMIS Presents Data from Alzheimer's Disease Program

    Bryan Mc Govern
    Jul. 19, 2017 10:43AM PST
    Biotech Investing

    ProMIS Neurosciences announced the presentation of its precision design approach and preclinical data for its lead product candidates, at the Alzheimer’s Association International Conference.

    ProMIS Neurosciences (TSX:PMN) announced the presentation of its precision design approach and preclinical data for its lead product candidates, at the Alzheimer’s Association International Conference.
    As quoted in the press release:

    Commenting on the ProMIS podium presentation at AAIC, Eugene Williams, ProMIS Executive Chairman stated: “We continue to make significant progress with our Alzheimer’s program, selectively targeting toxic amyloid beta oligomers, widely recognized at the conference to be a root cause of Alzheimer’s. The unique characteristics of our lead products in development, PMN310 and PMN350, distinguishes them from other antibodies targeting amyloid beta currently undergoing clinical trials and are designed to address observed issues of safety and efficacy”.
    Several presentations at the AAIC meeting by other specialist groups in the field also underlined the importance of selectively targeting and neutralizing toxic AbO for effective treatment of Alzheimer’s.

    Click here to read the full press release.

    Source: www.newswire.ca

    promis neurosciencespreclinical dataclinical trialsproduct candidates
    The Conversation (0)

    Go Deeper

    AI Powered
    Man holds hand to head as fragments break off representing Alzheimer's disease.

    Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies

    Actinogen

    Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×